What is the appropriate management for a patient with moderate biatrial enlargement, moderate mitral regurgitation, moderate tricuspid regurgitation, a normal‑sized left ventricle with preserved systolic function (ejection fraction ≈60 %), and a pacemaker lead positioned in the right ventricle?

Management of Moderate Biatrial Enlargement with Moderate Mitral and Tricuspid Regurgitation

This patient requires comprehensive evaluation to determine the etiology of the valve disease (primary vs. secondary), assessment of symptoms, and consideration for concomitant surgical intervention if left-sided valve surgery becomes indicated, as moderate tricuspid regurgitation with a pacemaker lead warrants specific attention to prevent progression.

Initial Diagnostic Approach

Determine Primary vs. Secondary Etiology

The distinction between primary (organic) and secondary (functional) regurgitation is critical for management decisions 1:

• Mitral regurgitation: Assess for leaflet pathology (prolapse, flail, rheumatic changes) vs. annular dilatation from atrial enlargement
• Tricuspid regurgitation: Evaluate for leaflet abnormalities vs. annular dilatation secondary to RV pressure/volume overload or atrial enlargement
• Biatrial enlargement pattern: Suggests possible atrial functional regurgitation, particularly if chronic atrial fibrillation is present 2

Critical Assessment Parameters

Obtain the following specific measurements:

• Tricuspid annular diameter: ≥40 mm or >21 mm/m² is significant 1, 3
• RV function and size: Progressive RV dilatation or dysfunction changes management
• Pulmonary artery systolic pressure: Values <35 mmHg associated with better prognosis 4
• Rhythm status: Atrial fibrillation drives atrial functional regurgitation 5, 2
• Symptom assessment: NYHA class, heart failure signs, exercise capacity

Management Algorithm

If Asymptomatic with Preserved RV Function

Medical management with close surveillance 1:

• Diuretics for volume management 1, 3
• Optimize treatment of underlying conditions (atrial fibrillation, pulmonary hypertension)
• Serial echocardiography every 6-12 months monitoring for:
  • Progressive RV dilatation or dysfunction
  • Worsening regurgitation severity
  • Development of symptoms

If Symptomatic Despite Medical Therapy

Refer to a comprehensive heart valve center for multidisciplinary team evaluation 6:

The presence of moderate regurgitation in both valves with biatrial enlargement suggests potential for progression and warrants specialized assessment.

If Left-Sided Valve Surgery Becomes Indicated

Concomitant tricuspid intervention should be strongly considered 1, 3:

• Class IIa recommendation: Surgery should be considered for moderate primary tricuspid regurgitation undergoing left-sided valve surgery 1
• Class IIa recommendation: Surgery should be considered for mild or moderate secondary tricuspid regurgitation with dilated annulus (≥40 mm or >21 mm/m²) undergoing left-sided valve surgery 3

Critical rationale: Addressing moderate TR at the time of mitral surgery prevents future progression and avoids high-risk isolated tricuspid reoperation 3. Delaying tricuspid intervention often results in irreversible RV dysfunction and poor outcomes.

Special Consideration: Pacemaker Lead

The presence of a pacemaker wire in the right ventricle adds complexity 1:

• Surgical technique must be adapted to the patient's condition and surgeon's experience
• Options include:
  • Tricuspid repair with lead in place (if anatomically feasible)
  • Lead extraction with reimplantation (if necessary)
  • Consideration of leadless pacing systems in select cases 7
• The lead does not preclude tricuspid intervention but requires specialized surgical planning

Monitoring for Progression

Key warning signs requiring intervention 1, 3:

• Development of symptoms (dyspnea, fatigue, peripheral edema)
• Progressive RV dilatation on serial imaging
• Decline in RV function (TAPSE <17 mm, RV free wall longitudinal strain worsening)
• Progression to severe regurgitation
• Worsening pulmonary hypertension

Common Pitfalls to Avoid

1. Underestimating tricuspid regurgitation severity: TR is frequently overlooked and requires careful evaluation 1. The presence of a pacemaker lead may contribute to or worsen TR.

2. Delaying tricuspid intervention: Waiting until isolated tricuspid surgery is needed carries significantly higher operative risk and worse outcomes due to irreversible RV dysfunction 3. The threshold for concomitant tricuspid repair should be low when mitral surgery is performed.

3. Ignoring annular dimensions: Even with moderate TR, an annulus ≥40 mm indicates high risk for progression and warrants intervention during left-sided surgery 3.

4. Overlooking atrial functional etiology: Biatrial enlargement with atrial fibrillation suggests atrial functional regurgitation, which may benefit from rhythm control strategies and consideration of concomitant atrial procedures during surgery 5, 2.

Prognosis Considerations

Moderate TR with preserved LVEF carries significant long-term risk 4:

• 3-year mortality approximately 31% in moderate TR patients
• Risk stratified by pulmonary pressures (better outcomes with PASP <35 mmHg)
• Combined moderate mitral and tricuspid regurgitation represents a distinctive clinical syndrome requiring integrated management 8